Last updated: July 31, 2025
Introduction
Israel Patent IL242395 pertains to a specific innovation within the pharmaceutical domain. While patent details are publicly accessible through the Israeli Patent Office, comprehensive analysis necessitates a thorough examination of its scope, claims, and positioning within the broader patent landscape. This document provides an in-depth analysis to inform stakeholders—pharmaceutical companies, patent attorneys, and R&D strategists—about the patent’s strategic significance and potential implications in drug development and intellectual property (IP) management.
Patent Overview and Background
IL242395, filed on (assumed date based on patent numbering conventions, e.g., circa early 2010s), appears to cover (hypothetically, as precise claims need review) a novel formulation or compound relevant to treatment of (specific disease area, e.g., neurodegenerative disorders). The patent is authored or held by (entity, e.g., a pharmaceutical company or research institution) with an emphasis on innovating existing drug paradigms or proposing enhanced delivery methods.
Given the typical scope of such patents, IL242395 likely claims a unique composition, process, or formulation, potentially including pharmaceutical complexes with specific physicochemical properties or innovative administration methods.
Scope of the Patent
The scope of IL242395 hinges primarily on its claims, which define the legal boundaries of the patent's protection. Generally, Israeli patents, much like those globally, contain two main types of claims:
- Independent claims: Broadly defining the core invention, serving as the primary scope.
- Dependent claims: Narrower claims adding specific details or embodiments.
Key aspects of the patent scope include:
-
Chemical Composition Claims:
If the patent involves a novel compound, the scope encompasses the precise molecular structure, derivatives, and salts claimed. For instance, claims may specify the chemical formula, stereochemistry, or unique substitutions that confer advantageous pharmacological properties.
-
Formulation and Delivery:
The patent may claim specific formulations—such as controlled-release matrices, nanoparticle carriers, or transdermal patches—especially if these formulations improve bioavailability or stability.
-
Method of Use:
Claims may include therapeutic methods—use of the compound for treating particular indications. Such method claims can be broad, covering any application within the designated disease area.
-
Processing or Synthesis Claims:
If a novel synthetic route is claimed, scope extends to the specific process steps, catalysts, or conditions.
-
Combination Claims:
Patents often include claims covering combinations of the asserted compound with other agents, enhancing therapeutic efficacy or reducing side effects.
Claims Analysis
Without full access to the claims text, a hypothetical review indicates that IL242395 likely emphasizes:
- Broad independent claims covering a novel chemical entity or composition with suspected broad applicability across multiple indications.
- Dependent claims restricting scope to specific derivatives, formulations, or dosing methods, which serve as fallback positions.
- Use claims dedicated to treatment methods, which may have varying enforceability depending on jurisdiction and evolving legal standards.
The breadth of the independent claims determines whether competitors can design around the patent. If claims are narrowly drafted, alternative compounds or formulations may evade infringement, but overly broad claims risk invalidation if prior art discloses similar inventions.
Patent Landscape Positioning
IL242395 resides within a complex patent landscape characterized by:
- Existing prior art: Patent or literature disclosures involving related compounds or formulations. For example, similar molecules may have base patents in other jurisdictions, necessitating a freedom-to-operate analysis.
- Global patent filings: Given Israel’s bilateral agreements and PCT cooperation, corresponding patents in key markets like the US, EU, and China likely exist or are pending, securing broader protection.
- Competitive landscape: Major pharmaceutical companies continually file follow-up patents to extend patent life or cover novel uses, creating a dense cluster of related patents. Monitoring such filings is critical for freedom-to-operate assessments.
- Patent expiry and supplementary protections: The patent’s lifespan affects strategic decisions—if close to expiration or facing potential challenge, companies may consider such factors in planning development pipelines.
Patent Validity and Enforceability
The validity of IL242395 depends on:
- Novelty: Confirmed if no prior art predates the filing.
- Inventive step (non-obviousness): Demonstrated through evidence that the invention is not an obvious extension of existing technology.
- Industrial applicability: Clear, as the invention pertains to pharmaceutical compositions—generally straightforward.
Legal challenges from competitors could revolve around prior art, claim construction, or obviousness arguments. Given Israeli Patent Office practices, patents remain enforceable unless successfully challenged in district courts or opposition proceedings.
IP Strategies and Implications
- Filing momentum: To maximize territorial coverage, patent holders should pursue filings in jurisdictions aligned with commercial markets.
- Supplementary protections: Considering data or supplementary patent applications for formulations, methods, or new indications strengthens IP position.
- Infringement risks: Competitors should analyze claim scope relative to their products, especially if broad claims cover core active ingredients or delivery mechanisms.
Conclusion
IL242395 exemplifies a targeted pharmaceutical patent with claims likely designed to balance broad protection with defendability. Its scope—primarily centered on a novel compound, formulation, or therapeutic method—positions it as potentially influential within its niche. The patent’s landscape is competitive, with various national and international filings demanding vigilant monitoring.
Key Takeaways
- The patent likely encompasses broad chemical, formulation, and use claims, emphasizing strategic patent drafting.
- Competitors must analyze claim language carefully to avoid infringement or to design around effectively.
- Strengthening patent protection may involve filing related applications targeting formulations, methods, or new indications.
- The patent’s validity hinges on this innovation being novel and non-obvious in light of prior art.
- An active monitoring strategy in related jurisdictions will be critical to sustain competitive advantage.
FAQs
1. What is the typical scope of a pharmaceutical patent like IL242395?
Pharmaceutical patents generally cover chemical compositions, specific formulations, manufacturing processes, and therapeutic methods. The scope depends on how broadly claims are drafted, balancing wide protection with legal robustness.
2. How does IL242395 compare to other patents in its field?
Without access to the claims, comparison is speculative. However, its contextual position depends on the specificity of claims, prior art references, and the claiming strategy—all factors influencing its strength relative to existing patents.
3. Can competitors develop similar drugs without infringing this patent?
If claims are narrowly drafted, designing alternative compounds or formulations that avoid the specific scope can potentially circumvent infringement. A detailed claim-by-claim analysis is essential.
4. How important is patent coverage in the Israeli market for drug development?
Israeli patent law provides robust protection, and local patents can block generic entry, incentivizing R&D investments. International protection via filings in metropolises enhances global market strategies.
5. What future actions should patent holders consider regarding IL242395?
They should evaluate filing continuation or divisional applications, pursue enforcement actions if infringement occurs, and monitor competitors’ filings for emerging challenges or infringing products.
References
- Israeli Patent Office Public Database. Patent IL242395. [Online] Available: [Insert URL]
- WIPO PCT Patent Application Publications. [Online]
- World Intellectual Property Organization. Guide to Patent Law and Practice. 2021.
